Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed Hodgkin's lymphoma of any histology~* Unfavorable disease required~  * Clinical stage IIIA, IIIB, IV, or IIB (non-bulky)~ * Locally extensive stage I or II with either of the following:~    * Mediastinal mass greater than 1/3 the maximum intrathoracic diameter~   * Two or more extranodal sites~PATIENT CHARACTERISTICS:~Age:~* 18 to 60~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* No prior malignancy except nonmelanomatous skin cancer~* No significant concurrent illness that precludes protocol participation~PRIOR CONCURRENT THERAPY:~* No prior treatment for Hodgkin's lymphoma~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Combination Chemotherapy (Stanford V) (Type: EXPERIMENTAL): A combination chemotherapy regimen consisting of mechlorethamine, doxorubicin hydrochloride, vinblastine, vincristine, bleomycin, etoposide and prednisone, administered on a compressed schedule

Based on this trial design, predict the completion outcome and termination type (if applicable).